tirzepatide and ulcerative colitis If you are living with Crohn's disease or you have recently started a GLP-1 medication like semaglutide or tirzepatide, you are not alone. Patients regularly ask me whether these GLP-1 receptor agonists in IBD:

Transparent pricing should itemize costs separately so you understand what you're paying for: active ingredients, compounding labor, vial preparation, shipping, and consultation support

Experimental study on the effect of luteolin on the proliferation, apoptosis and expression of inflammation-related mediators in lipopolysaccharide-induced keratinocytes

Lipopolysaccharide (LPS, batch number L6529) was acquired from Sigma

2 people out of 100 who received drug X experienced a heart attack after 3 years 4 people out of 100 who received the placebo experienced a heart attack after 3 years We divide 4/100 to get the baseline absolute risk in this placebo group (often referred to as the control group), which is 4% We then divide 2/100 to get the absolute risk in the group taking the medication (often referred to as the exposure or intervention group), which is 2% To understand the relative risk, we divide the exposed group with the placebo group: 2%/4% = 50% We can then calculate the difference between 2% and 4% to understand the absolute risk, which would be 2% This means that drug X causes a 50% relative drop in the rate of heart attacks compared to the placebo group